跳至主要内容
临床试验/NCT03855956
NCT03855956已完成不适用

A Randomized, Double-blind, Controlled, Clinical Food Study to Evaluate the Effect of KB174 Compared to an Easily Digestible Polysaccharide on Function and Structure of the Gut Microbiome in Subjects With Well-compensated Cirrhosis

Kaleido Biosciences8 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2019年2月27日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
40
试验地点
8
主要终点
Change in 15N in urine in response to an amino acid challenge, from Baseline to Tracer Period 2, for KB174 compared to maltodextrin.

研究概览

简要总结

This randomized, double-blind, controlled, clinical food study aims to explore KB174, a novel mixture of oligosaccharides, and maltodextrin, an easily digestible polysaccharide, on gut microbiome structure and function in subjects with well-compensated cirrhosis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Be able and willing to provide written informed consent
  • Be male or female, 18 to 70 years of age (inclusive)
  • Have a body mass index (BMI) ≥ 20.0 and < 40.0 kg/m2
  • Well-compensated cirrhosis
  • Negative for hepatocellular carcinoma (HCC)
  • Adequate safety laboratory values at Screening.
  • Be willing to maintain a stable diet throughout the course of the study, and willing to continue usual exercise routine
  • If of child bearing potential must follow contraceptive requirements of the protocol
  • Have reliable internet access

排除标准

  • Have evidence of decompensated liver disease.
  • History or active GI disease.
  • Prior solid organ transplantation, including liver transplantation or on liver transplant waiting list.
  • Subject has a history of drug and/or alcohol abuse.

结局指标

主要结局

Change in 15N in urine in response to an amino acid challenge, from Baseline to Tracer Period 2, for KB174 compared to maltodextrin.

时间窗: Day -3 to Day 28.

Change in 15N in urine in response to an amino acid challenge during Baseline (pre-study compound consumption) versus post-28-day study compound compound consumption.

次要结局

  • Change in 15N in stool in response to an amino acid challenge, from Baseline to Tracer Period 2, for KB174 compared to maltodextrin.(Day -3 to Day 29.)
  • Change in 15N-urea in urine in response to an amino acid challenge from baseline to Tracer Period 2, for KB174 compared to maltodextrin.(Day -3 to Day 29.)
  • Change in 15N-urea in stool in response to an amino acid challenge from baseline to Tracer Period 2, for KB174 compared to maltodextrin.(Day -3 to Day 29.)
  • Change in total nitrogen in blood in response to an amino acid challenge, from Baseline to Tracer Period 2, for KB174 compared to maltodextrin.(Day -3 to Day 27.)
  • . Change in total nitrogen in stool in response to an amino acid challenge, from Baseline to Tracer Period 2, for KB174 compared to maltodextrin.(Day -3 to Day 29.)
  • Change in ammonia in blood for KB174 compared to Maltodextrin.(Day -3 to Day 43.)
  • Change in total urea in urine in response to an amino acid challenge from baseline to Tracer Period 2, for KB174 compared to maltodextrin.(Day -3 to Day 29.)
  • Incidence of treatment-emergent adverse events from baseline to end of study.(Day -7 through Day 43 visit.)
  • Change in total nitrogen in urine in response to an amino acid challenge, from Baseline to Tracer Period 2, for KB174 compared to maltodextrin.(Day -3 to Day 29.)
  • Change in Gastrointestinal Tolerability Questionnaire (GITQ) through the collection of daily patient questionnaires.(Day -7 through Day 43.)
  • Incidence of serious adverse events from base baseline to end of study.(Day -7 through Day 43.)
  • Change in Bristol Stool Scale (BSS) through the collection of daily patient questionnaires(Day -7 through Day 43.)

研究者

发起方
Kaleido Biosciences
申办方类型
Industry
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验